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in astrocytes.11 Furthermore, KIR4.1 loss will also occur 
when oligodendrocytes are lost in the demyelinating 
process or astrocyte processes are damaged by 
mechanisms independent of antibody-mediated and 
complement-mediated immune reactions.12 Finally, 
technical issues of immunocytochemistry (eg, use of 
frozen vs paraffi  n sections) and exact staging of lesions 
might partly diff er between the studies.  
Do these fi ndings, from independent research 
groups, mean that research into KIR4.1 in multiple 
sclerosis should end? We hope not. The reasons for 
the discrepancies between the investigations might 
be at least partly technical and call for additional 
work. Pathological studies using diff erent analytical 
approaches are also warranted to deepen the 
understanding of this potentially revolutionary aspect of 
multiple sclerosis research. Many unanswered questions 
related to KIR4.1 function still remain. The coexpression 
of KIR4.1 and aquaporin-4 channels in endfeet of 
astrocytes and their synergistic eff ect in maintaining 
osmotic homoeostasis is intriguing, especially when 
considering that most retinal pathological changes 
characterised by Müller cell damage are accompanied 
by changes of the amount or spatial distribution of 
both channels. Finally, the potential relation between 
anti-KIR4.1 antibodies and a more general dysfunction 
of immune-mediated mechanisms in patients with 
multiple sclerosis deserves further investigation.
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The Glasgow Coma Scale: time for critical reappraisal?
40 years ago, Teasdale and Jennett1 published their 
milestone Article on the Glasgow Coma Scale in The 
Lancet. This standardised clinical scoring system 
allowed clinicians to assess and communicate 
neurological change and quantifi cation of 
consciousness; it also improved outcome prediction 
and guided treatment decisions. As reviewed by 
Teasdale and colleagues2 in The Lancet Neurology, 
the pioneering work of the Glasgow investigators 
revolutionised acute brain injury research and set the 
start of the science of coma, permitting multicentre 
trials and epidemiological studies that continue to 
develop rational algorithms for the treatment (or 
withdrawal thereof) of comatose patients. The role 
of the scale can hardly be oversetimated and it’s 40th 
anniversary should be one of celebration. 
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Since its original publication, investigators 
have pointed to the possible shortcomings of the 
Glasgow Coma Scale and have proposed alternative 
consciousness scales; however, none have seen the same 
success as the original.3 Will the Glasgow Coma Scale 
one day be dethroned and replaced, or will it remain 
unmovable for decades to come? 
For clinical diagnosis, we note that the Glasgow 
Coma Scale was not designed to diff erentiate 
post-coma patients who awake (ie, open eyes 
to stimulation) and progressively (over days to 
weeks) enter a vegetative state (now also labelled 
unresponsive wakefulness syndrome)4 or a minimally 
conscious state.5 Minimally conscious state refers 
to those patients who show minimum (and often 
fl uctuating) signs of consciousness but are unable to 
reliably communicate (table). This recently defi ned 
disorder has been further subcategorised based on 
the complexity of patients’ behaviours: minimally 
conscious state describes low-level responses (ie, 
visual pursuit, localisation of noxious stimulation, or 
contingent behaviour such as appropriate smiling or 
crying to emotional stimuli) and minimally conscious 
state PLUS describes high-level behavioural responses 
(ie, command following, intelligible verbalisations, 
or non-functional communication).6 It is important 
to identify, as early as possible, minimal signs of 
consciousness in non-communicative patients after 
brain injury. Patients in minimally conscious state 
have preserved emotional processing, including 
pain perception,7 needing appropriate clinical and 
analgaesic management. 
The Glasgow Coma Scale was developed before 
the existence of current nosological criteria and 
neuroanatomical understanding of disorders 
of consciousness. One of the most frequently 
observed clinical signs heralding the transition from 
a vegetative-unresponsive state to a minimally 
conscious state is the recovery of visual pursuit.8 
However, the Glasgow Coma Scale does not test 
for eye tracking (which has been shown to be best 
assessed by presentation of a moving mirror).9 The 
scale Full Outline of UnResponsiveness (FOUR; an 
acronym for the number of components tested: eye, 
motor, brainstem, and respiratory function, and 
for the maximum score assigned to each of these 
components)10 assesses visual tracking explicitly and 
so can identify patients in a minimally conscious state 
MINUS who have non-verbal signs of consciousness 
not detected by the Glasgow Coma Scale (a diagnostic 
error rate we estimate at 10% in our intensive care 
population of patients with acute brain injury).11 
In addition, FOUR also tests specifi cally for eye 
movements or blinking to command (requesting to 
open the eyes manually if closed), permitting the 
early detection of locked-in syndrome. This ability is 
much welcomed, given that clinicians might miss this 
infrequent diagnosis in up to half of patients.12
In terms of outcome prediction, some investigators 
have critisised the Glasgow Coma Scale because it 
does not incorporate brainstem refl exes (eg, pupil and 
cornea) or include other clinical signs of bad prognosis 
such as generalised myoclonus status epilepticus.3,10 
Another reservation is that the increasing use of 
intubation has made the scale’s verbal component 
impossible to measure in many coma patients.8 
For this reason, the FOUR scale10 proposed a hand-
position test in which the patient is asked to make 
a thumbs-up, fi st, or victory sign. This test might be 
an alternative to the verbal (V) score of the Glasgow 
Coma Scale and remains testable in intubated patients 
(about three quarters of the patients with acute brain 
injury in our intensive care units).11
Thanks to its ingenious simplicity and ease of use, 
the Glasgow Coma Scale is, and remains, the widest 
used and most validated scale worldwide but, as 
highlighted by Teasdale and colleagues,2 it should 
evidently not be assessed or considered in isolation. As 
any other medical scale, it reduces the complexity of 
a clinical reality to a set of numbers. The past 40 years 
have proven that this reductionist yet standardised 
approach is extremely powerful. To replace or revise 
such a well-anchored medical standard will not happen 
overnight. Several other scales and adaptations of the 













Communication Absent Absent Absent Absent Present
Response to command Absent Absent Absent Present Present
Non-refl ex behavior Absent Absent Present Present Present
Eye-opening Absent Present Present Present Present
Table: Clinical characteristics of coma and related states
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none has been able to change clinical practice.3 In the 
future, multidimensional diagnostic and prognostic 
assessements will probably integrate information 
from genomics, biomarkers, electrophysiology, 
and neuroimaging techniques and classifi ers,13 with 
knowledge from standardised behavioral scales 
(including user-independent automated pupil14 and 
visual pursuit assessments). 
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